ophthalmology-summit-2019-keynote

8 / 8

Ophthalmology Summit 2019 Ophthalmology Case Reports | Volume 3
Page37
March 27-28, 2019 | Amsterdam, Netherlands
2nd GLOBAL
OPHTHALMOLOGY SUMMIT 2019
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
HAS ANTI-VEGF TAMED NAMD?
N eovascular Age related Macular Degeneration (neovascular AMD) is a
chronic, complex disease driven by multiple pathogenic mechanisms.
Upregulation of vascular endothelial growth factor (VEGF) is a well-docu-
mented pathogenic mechanism in neovascular AMD. VEGF is released by
Retinal Pigment Epithelium (RPE) as a stress signal and hypoxia that initi-
ates a cascade of angiogenic responses at the choroidal endothelium level.
This increases vessel permeability (causing fluid leakage) and promotes the
growth of abnormal blood vessels (neovascularization) under and/or within
the retina.
Anti-VEGF therapy can yield excellent visual outcomes by selectively binding
to or deactivating the transmission of VEGF and causing rapid resorption of
sub-retinal fluid. Keeping the retina dry seems to be important to achieve
these best outcomes. However, despite optimal Anti-VEGF therapy, vision
may decline in the long-term because it may lead to more retinal atrophy.
This research is a systematic review of the effect of Anti-vascular endotheli-
al growth factor therapy in neovascular AMD. It covers the various aspects
of treatment protocol in neovascular AMD by comparing fixed with flexible
treatment approaches. A formal search of Embase, Cochrane and Medline
were performed for consistent and well-documented long-term visual out-
come of anti-VEGF in neovascular AMD. Different treatment regimens were
investigated. Studies were reviewed independently for methodology, inclu-
sion and exclusion criteria and endpoints. Benefit/risk ratio of treatment is a
key consideration in treatment of neovascular AMD.
It can be concluded by the research that flexible dosing regimens allow per-
sonalized therapy, avoid over- or under-treatment and facilitate the mainte-
nance of optimal outcomes whilst minimizing treatment burden.
Gaurav Arora, Ophthalmol Case Rep 2019, Volume 3
Gaurav Arora is a vitreo-retinal consultant
and regional medical head at Dr. Agarwal’s
Eye Hospital, Hyderabad. He has vast experi-
ence in diagnosis and management of vari-
ous retinal conditions. He has skill, proficien-
cy & experience of managing vitreoretinal
conditions, with expertise in Phacoemulsifi-
cation surgeries. He has special expertise in
sutureless Glued IOL technique. He has ex-
tensive experience of managing diabetic ret-
inopathies, vasculopathies, retinal holes and
breaks etc. He has presented many papers
and videos at national level. He has worked
with Dr Lipshitz (Israel) for the unique Mirror
Telescopic Intraocular (MTI) lens study. He
has also participated as an Ophthalmologist
in WHO- N.P.C.B’s rapid assessment of Tra-
choma survey and as an Epidemiologist in
the N.P.C.B’s rapid assessment of avoidable
blindness survey in 2006. His current area of
interest is research in macular pathologies.
Gaurav Arora
Dr. Agarwal’s Eye Hospital, India
BIOGRAPHY